Epidermal growth factor receptor (EGFR) mutations, mainly exon 19 deletion and exon 21 L858R mutations, are the most commonly detected oncogenic drivers in approximately 20%–50% of stage IV NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.